<?xml version="1.0" encoding="UTF-8"?>
<p>Prostate cancer is the most common malignancy in male, especially in Western World (
 <xref rid="B16" ref-type="bibr">Ferlay et al., 2015</xref>; 
 <xref rid="B30" ref-type="bibr">Ku et al., 2019</xref>; 
 <xref rid="B49" ref-type="bibr">Siegel et al., 2020</xref>). Despite substantial advances in diagnosis and therapeutics in prostate cancer, it still ranks the first cause of cancer mortality of male in the United States, which caused 33,330 deaths in 2020 statistics (
 <xref rid="B49" ref-type="bibr">Siegel et al., 2020</xref>). Studies regarding molecular alterations of prostate cancer offered mounts of potential diagnostic and therapeutic targets, with non-coding RNAs playing important roles (
 <xref rid="B30" ref-type="bibr">Ku et al., 2019</xref>).
</p>
